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Abstract 
Oral anticoagulant therapy (OAT) with direct oral
anticoagulants (DOACs) is the established treatment to reduce
thromboembolic risk in patients with atrial fibrillation (AF).
Bleeding risk scores are useful to identify and correct factors
associated with bleeding risk in AF patients on OAT. However, the
clinical scenario is more complex in patients with a previous
bleeding event, and the decision about whether and when starting
or re-starting OAT in these patients remains a contentious issue.
Major bleeding is associated with a subsequent increase in both
short- and long-term mortality, and even minimal bleeding may
have a prognostic importance because it frequently leads to
disruption of antithrombotic therapy. There is an unmet need for
guidance on how to manage antithrombotic therapy after bleeding
has occurred. While waiting for observational and randomized data
to accrue, this paper offers a perspective on managing
antithrombotic therapy after bleeding in older patients with AF.
Introduction
Bleeding is a frequent complication of the management of
patients with atrial fibrillation (AF). Randomized trials have shown
a risk of major bleeding around 2-5% per year in patients with AF
treated with oral anticoagulant therapy (OAT) [1]. Major bleeding
is associated with a subsequent increase in both short- and long-
term mortality [2]. Moreover, discontinuation of antithrombotic
drugs and prothrombotic responses following a bleeding may lead
to an increased rate of thrombotic events due to the progressive
recovery of platelet function and coagulation activity. It is well
known that patients who are more likely to suffer from bleeding
complications of antithrombotic therapy also tend to be at higher
risk of thrombotic events [3]. Ageing is associated with a
progressive increase of bleeding and thrombotic risk. In a
population study on 359,166 people without cardiovascular (CV)
disease not receiving antithrombotic therapies, the annual risk of
major gastrointestinal bleeding was 0.6% in men and women aged
30-39 years and 2.3% and 1.6% in men and women, respectively,
aged 70-79 years [4]. The annual risk of major intracranial bleeding
was 0.03% in people aged 30-39 years, and 0.3% and 0.2% in men
and women, respectively, aged 70-79 years [4]. There are few data
on bleeding risk in the oldest-old patients with AF. A matched
cohort study including AF patients treated with vitamin K
antagonists (VKAs) at a thrombosis service demonstrated that
bleeding risk is only mildly increased in people aged 90 years and
over compared with patients aged 70 to 79 years, whereas patients
in their 80s had a risk of bleeding comparable with that of patients
in their 70s [5]. Interestingly, there was a steeper increase in the
risk of thrombotic events in those aged 90 years and over compared
with patients in their 70s and 80s [5]. Moreover, the risk of bleeding
in these very old patients was not significantly affected by the
quality of warfarin therapy [5]. These recent findings are in keeping
with a previous study which showed that, among 4093 patients aged
80 years and over receiving VKAs for AF or pulmonary embolism,
the annual rate of bleeding was 2.22% in those aged ≥85 years
compared with 1.71% in those aged <85 years [6]. Moreover,
82.2% of bleeding events occurred in patients with an international
normalized ratio (INR) in the range 2.0-3.0 [6]. Altogether, these
findings suggest that there is a mild increase in the bleeding risk in
advanced age, and that OAT, rather than directly “causing”, makes
evident underlying silent bleeding. This is one of the main reasons
why current scores recommended for estimating bleeding risk have
demonstrated similar, albeit modest, performance in predicting
OAT-associated bleeding in patients with AF [7]. 
In daily clinical practice older AF patients with a previous
bleeding represent a common clinical scenario. Whether and when
to start or re-start OAT in these patients is a complex decision,
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involving a careful evaluation of potential harm vs benefit ratio.
Patients with recent bleeding have been excluded from most
randomized trials of antithrombotic therapy and rigorous evidence
to inform decisions is scarce. Clearly, balancing the risks of further
bleeding against potentially fatal thrombotic events is critical for
decisions about if and when to start or restart antithrombotic therapy
after bleeding. In this paper we will review evidences to inform
clinical decisions in this setting of patients. 
Methods
Scientific literature focused on use of OAT and DOACs in older
persons with previous bleeding events published in the last 8 years
was retrieved by the authors from the MEDLINE database using
the terms “atrial fibrillation” AND “oral anticoagulant therapy”, OR
“new oral anticoagulants” OR “direct oral anticoagulants”, AND
“aged” OR “elderly” OR “older” as keywords. Reviews,
recommendations and expert opinions, as well as clinical trials and
large observational studies in English published until March 2019
were systematically analyzed and included according to their
relevance to the objective. Additional references were obtained from
the reference list of the selected full-text manuscripts.
Results
In a retrospective cohort study that enrolled 1329 AF patients
(mean age 76 years, 45% women) who developed gastrointestinal
bleeding (GIB) while on anticoagulation from 2005 to 2010,
warfarin was restarted in 653 (49.1%) patients [8]. Compared with
patients who did not receive OAT, those who were restarted with
VKAs had better cumulative survival (HR 0.67, 95% CI: 0.56-0.81)
and lower one-year cumulative incidence of thromboembolic events
(HR 0.71. 95% CI: 0.54-0.93) without a significant increase in the
90-days cumulative incidence of recurrent GIB [8]. Restarting OAT
7 to 15 days after bleeding events was associated with more
favorable cumulative survival and clinical benefit including
recurrent bleeding and thromboembolism [8]. A recent prospective
observational cohort study on 197 consecutive patients (mean age
75 years, 60% AF) hospitalized for GIB while on OAT, investigated
90 days cumulative incidence of thromboembolic events, hospital
readmissions related to GIB, and mortality in those who resumed
anticoagulation and those who had anticoagulation discontinued [9].
The adjusted hazard ratios for continuing vs cessation of OAT were
0.121 (95% CI: 0.006-0.813, p=0.03) for thromboembolism, 2.17
(95% CI: 0.861-6.67, p=0.10) for recurrent GIB, and 0.632 (95%
CI: 0.216-1.89, p=0.40) for all-cause death [9]. In a retrospective
Danish cohort study in the period 1996-2012 which enrolled 4602
AF patients (mean age 78 years) discharged after GIB, 27,1% did
not resume antithrombotic therapy [10]. In the whole sample,
overall 2-year mortality was 39.9%, major bleeding and recurrent
GIB occurred in 17.7% and 12.1% of patients, respectively, whereas
12% of patients experienced a thromboembolic event. Compared
with patients who did not resume OAT, all-cause mortality and
thromboembolism were significantly lower either in patients who
restarted OAT (HR 0.39, 95% CI: 0.34-0.46 and HR 0.41, 95% CI:
0.31-0.54, respectively) and in those who restarted OAT plus
antiplatelet therapy (HR 0.41, 95% CI: 0.32-0.52 and HR 0.54, 95%
CI: 0.36-0.82, respectively). Major bleedings, but not GIB
recurrence, were significantly higher in those who restarted OAT
and OAT plus antiplatelet therapy (HR 1.37, 95% CI: 1.06-1.77, and
HR 1.49, 95% CI: 1.32-1.91, respectively) [10]. A recent
retrospective analysis of medical claims data from the Truven
Health Marketscan Commercial Claims and Encounters Database,
from January 1, 2010, through December 31, 2014, included 1338
adults (mean age 79 years) treated with DOACs and hospitalized
for GIB [11]. DOACs were restarted in 586 patients; older patients
requiring blood and intensive care were less likely to restart DOAC
therapy. In the whole sample resuming DOAC was not associated
with 90-day thromboembolism and recurrence of GIB [11].
A recent study aimed to evaluate current clinical evidence for
management of OAT after GIB, with an emphasis on whether to,
when to, and how to resume an anticoagulation therapy [12]. A total
of 9 studies were identified. Four retrospective cohort studies
showed that resuming anticoagulation therapy was associated with
significantly lower rate of thromboembolism (TE) in the general
population. Meta-analyses and prospective cohort studies also
supported this finding. Two retrospective cohort studies indicated
an increase in GIB when anticoagulation reinitiation occurred in
less than 7 days without a decrease in TE. [12]. Resuming therapy
between 7 and 15 days did not demonstrate a significant increase in
GIB or TE [12]. A large retrospective study showed that apixaban
was associated with the significantly lowest risk of GIB compared
with both rivaroxaban and dabigatran.
The Authors concluded that OAT resumption is recommended,
with resumption being considered between 7 and 14 days following
GIB regardless of the therapy chosen [12]. Data for warfarin
management after GIB should be applied with caution to direct oral
anticoagulants (DOACs) because of the quicker onset and
experimental nature of reversal agents. Apixaban may be a preferred
option when restarting a DOAC therapy [12]. A recent review and
meta-analysis, aiming to determine the risks of recurrent GIB,
thromboembolism and death in patients who resumed OAT
compared to those who did not, identified 12 observational studies
involving 3098 patients [13]. There was an increased risk of
recurrent GIB (RR 1.91, 95% CI 1.47-2.48, I2 = 0%, 11 studies),
and a reduced risk of thromboembolism (RR 0.30, 95% CI 0.13-
0.68, I2 = 59.8%, 9 studies) and death (RR 0.51, 95% CI 0.38-0.70,
I2 = 71.8%, 8 studies) in patients who resumed OAC compared to
those who did not. Although eleven studies were judged to be at
serious risk of bias due to confounding, these results suggest that
resuming OAT after OAT-related GIB appears to be associated with
an increase in recurrent GIB, but a reduction in thromboembolism
and death [13].
There are few observational cohort studies which investigated
the clinical benefit of restarting OAT after intracranial hemorrhage
(ICH). A recent review and meta-analysis concluded that
reinstitution of OAT after ICH was associated with a lower risk of
thromboembolic complications and a similar risk of ICH recurrence
[14]. A recent study examined the timing of DOAC resumption and
factors that influence decision-making in DOAC resumption in 43
patients with ICH who were treated with DOAC for nonvalvular
atrial fibrillation before ICH onset [15]. DOAC were resumed in 19
of 39 (49%) acute ICH survivors and were not resumed in 24
patients, including 4 deceased patients. The National Institutes of
Health Stroke Scale score at admission tended to be higher in the
no resumption group (median, 17) than in the resumption group
(median, 6) (p=0.119). The modified Rankin Scale score was
slightly poorer in the no resumption group (median, 4) than in the
resumption group (median, 3) (p=0.070). In the resumption group,
DOAC were resumed at a median of 11 days (interquartile range,
5-21 days) after ICH onset. The modified Rankin Scale score at
discharge was positively correlated with the days of DOAC
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resumption (R2 = 0.31, p=0.013). The Authors concluded that early
resumption of DOAC for ICH in AF patients is considered to be
safe, and that the functional outcome was associated with not only
resumption of DOAC but also the timing of resumption [15].
Perreault et al. investigated whether starting OAT among 683 older
AF patients (mean age 83 years) after an ICH was associated with
a lower risk of ischemic stroke/systemic embolism (IS/SE) and
mortality but offset by an increase in major bleeding [16]. The rates
(per 100 person-years) for IS/SE, death, ICH and major bleeding
were 3.3, 40.6, 11.4, and 2.7 for the no OAC group; and 2.6, 16.3,
5.2, and 5.2 for the OAC group, respectively. The absolute hazard
ratio for IS/SE and death were 0.10 (95% CI: 0.05 to 0.21), 0.43
(95% CI, 0.19 to 0.97) for recurrent ICH and 1.73 (95% CI, 0.71 to
4.20) for major extracranial bleeding comparing OAT exposure to
non-exposed. The Authors concluded that initiating OAT after ICH
in older individuals with AF is associated with a reduction of IS/SE
and mortality, supporting its use after ICH bleeding [16].
A recent Danish cohort study included 4541 OAT treated AF
patients (mean age 81 years) experiencing traumatic injury during
the period 2005-2016: 60,7% of patients resumed warfarin-based
OAT and 16,7% resumed DOAC [17]. Compared with patients who
did not restart OAT, resumption of warfarin or DOACs was
associated with significantly lower hazards of all cause mortality
(0.48, 95% CI: 0.42-0.53, and 0.55, 95% CI: 0.47-0.66,
respectively) and ischemic stroke (0.56, 95% CI: 0.43-0.72, and
0.54, 95% CI: 0.35-0.82, respectively), at the cost of an increased
hazard of major bleeding in those receiving VKAs (1.30, 95% CI:
1.03-1.64) [17].
Discussion
The decision about whether and when to start or resume OAT
following an episode of GIB must balance the risks of
thromboembolism and recurrent GIB. This decision is even more
complex in patients who recovered from an ICH. Most of
observational studies suggest that the net clinical benefit favors
resuming OAT, with a reduced risk of thromboembolism and death,
despite an increase in GIB. Importantly, the clinical impact of GIB
and thrombotic events are not equivalent. The case-fatality rate of
OAT-related bleeding is 8-13% [18-20]. In comparison, the risk of
death, institutionalization due to stroke, or disability at 3 months
was 41% for all strokes in a European stroke registry [21].
Interestingly, in a retrospective cohort study in Medicare
beneficiaries between January 1, 2011 and September 30, 2015 there
were 1,643,123 patients with 1,713,183 new episodes of oral
anticoagulant treatment (mean age 76.4 years) [22]. Among patients
initiating OAT, incidence of hospitalization for upper GIB was
highest in patients prescribed rivaroxaban and the lowest in patients
prescribed apixaban. For each anticoagulant the incidence of
hospitalization for upper GIB was lower among patients who were
receiving proton pump inhibitor co-therapy [22].
However, most of the evidence supporting the initiation or re-
initiation of OAT after a major bleeding comes from observational
cohort studies which may be heavily flawed by several limitations.
These observational studies are highly heterogeneous in the pooled
estimates for thromboembolism and mortality. More important, all
these studies shared a high potential risk of bias due to baseline
confounding. Possible confounders included age, indication for
OAT, source of bleeding, risk of thrombosis, risk of recurrent
bleeding, and comorbidities. In the absence of randomization,
differences in baseline characteristics which are prognostic for
outcomes may have influenced the decision whether or not
resuming OAT. Therefore, the mortality benefit observed in most
of these studies might be at least in part accounted for by a higher
prescription of OAT to patients with better general health status.
Moreover, in all of these studies involving older AF patients there
is no mention of some comprehensive geriatric assessment, even if
there is strong evidence that geriatric syndromes may heavily affect
either OAT use and survival in these patients [23-27]. Therefore, in
the absence of high-quality data regarding the optimal timing of
resumption and type of OAT in this setting, decision-making should
be individualized with discussion about the risks and benefits and
incorporating patient values and preferences.
The European Society of Cardiology Working Group on
Thrombosis has recently released an expert consensus focused on
the management of antithrombotic therapy in AF patients after a
bleeding event [28]. Patients with AF were categorized according
to the estimated thrombotic risk as very high (including those with
CHA2DS2-VASC score ≥6, or mechanical mitral valves or cardiac
assist devices), high (including those with CHA2DS2-VASC
score=4-5 or a mechanical aortic bileaflet valve) and moderate
(CHA2DS2-VASC score=2-3) [28]. Similarly, an expert consensus
panel of the American College of Cardiology identified high
thrombotic risk in AF patients as the presence of at least one of
CHA2DS2-VASC score ≥6, stroke/Transient Ischemic Attack within
3 months, stroke risk ≥10% year, rheumatic valve disease or mitral
stenosis [29]. The European expert panel also provided a consensus
definition of recurrent bleeding risk categories, including a very
high-risk group (ICH where no treatment is possible or effective,
and life-threatening extracranial bleeding where the source of
bleeding is either not identified or identified but not treated
effectively), and a high risk group (major extracranial bleeding
where the source is identified but not treated effectively and
definitively) [28]. Clinical decisions are extremely complex in
patients fulfilling either very high- or high-risk features for
thrombotic and bleeding events. On this background, flow-charts
for (re)-initiation of OAT after GIB and ICH were provided [28,29],
including left atrial appendage occlusion for patients deemed at high
or very high thrombotic and bleeding risks. In this context, we
believe that older age per se should not be considered the best factor
to be considered among variables for the net assessment in favour
of withholding OAT in elderly people: rather, a careful geriatric
assessment may provide physicians a more reliable evaluation of
the net clinical benefit of OAT in these elderly patients [30-32].
In conclusion, the decision about whether or not to start or
reinitiate OAT in older AF patients with a previous bleeding should
be individualized and based on a careful evaluation of thrombotic
and bleeding risks, with discussion about the risks and benefits and
incorporating patient values and preferences. In this setting, a
thorough comprehensive geriatric assessment of general health
status and estimated survival may assist physicians in the decision-
making for older complex patients.
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